Andrea Milelli
Overview
Explore the profile of Andrea Milelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Milelli A, Catanzaro E, Greco G, Calcabrini C, Turrini E, Maffei F, et al.
Eur J Med Chem
. 2024 Oct;
280:116936.
PMID: 39395301
In search of semisynthetic derivatives with increased antitumor activity, we condensed sulforaphane (SFR) with rhodol, a fluorophore platform capable of modifying the intracellular trafficking and pharmacokinetics of the linked molecules....
2.
Guardigni M, Greco G, Poeta E, Santini A, Tassinari E, Bergamini C, et al.
RSC Med Chem
. 2024 Jun;
15(6):2045-2062.
PMID: 38911150
Alzheimer's disease (AD) and cancer are among the most devastating diseases of the 21st century. Although the clinical manifestations are different and the cellular mechanisms underlying the pathologies are opposite,...
3.
Santini A, Tassinari E, Poeta E, Loi M, Ciani E, Trazzi S, et al.
ACS Chem Neurosci
. 2024 May;
15(11):2099-2111.
PMID: 38747979
Despite recent FDA approvals, Alzheimer's disease (AD) still represents an unmet medical need. Among the different available therapeutic approaches, the development of multitarget molecules represents one of the most widely...
4.
Nordio G, Piazzola F, Cozza G, Rossetto M, Cervelli M, Minarini A, et al.
Molecules
. 2023 Sep;
28(17).
PMID: 37687158
Monoamine oxidases (MAOs) are well-known pharmacological targets in neurological and neurodegenerative diseases. However, recent studies have revealed a new role for MAOs in certain types of cancer such as glioblastoma...
5.
Guardigni M, Pruccoli L, Santini A, De Simone A, Bersani M, Spyrakis F, et al.
ACS Chem Neurosci
. 2023 May;
14(11):1963-1970.
PMID: 37218653
Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine kinase and an attractive therapeutic target for Alzheimer's disease. Based on proteolysis-targeting chimera (PROTAC) technology, a small set of novel GSK-3β degraders...
6.
Espinoza-Chavez R, Salerno A, Liuzzi A, Ilari A, Milelli A, Uliassi E, et al.
ACS Bio Med Chem Au
. 2023 Apr;
3(1):32-45.
PMID: 37101607
Targeted protein degradation (TPD) is emerging as one of the most innovative strategies to tackle infectious diseases. Particularly, proteolysis-targeting chimera (PROTAC)-mediated protein degradation may offer several benefits over classical anti-infective...
7.
Reyes E, Prieto L, Milelli A
Molecules
. 2023 Jan;
28(1).
PMID: 36615465
Majority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number...
8.
Ragno R, Minarini A, Proia E, Lorenzo A, Milelli A, Tumiatti V, et al.
J Chem Inf Model
. 2022 Aug;
62(16):3910-3927.
PMID: 35948439
Natural polyamines (PAs) are key players in cellular homeostasis by regulating cell growth and proliferation. Several observations highlight that PAs are also implicated in pathways regulating cell death. Indeed, the...
9.
Salerno A, Seghetti F, Caciolla J, Uliassi E, Testi E, Guardigni M, et al.
J Med Chem
. 2022 Jul;
65(14):9507-9530.
PMID: 35816671
Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this...
10.
Loi M, Gennaccaro L, Fuchs C, Trazzi S, Medici G, Galvani G, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34073043
Mutations in the X-linked cyclin-dependent kinase-like 5 () gene cause a rare neurodevelopmental disorder characterized by early-onset seizures and severe cognitive, motor, and visual impairments. To date there are no...